

solvate thereof according to claim 9, wherein X_2 is a nitrogen atom.

11. The pyridine derivative or the pharmaceutically acceptable salt thereof, or the solvate thereof according to any of claims 1 to 10, wherein R_3 is a hydrogen atom, an alkyl group having 1 to 6 carbon atoms (which may optionally be substituted with one or more of a hydroxyl group, an amino group, a dialkylamino group having 1 to 6 carbon atoms which may optionally form a ring, an imidazole ring, a pyrazole ring, a pyrrolidine ring, a piperidine ring, a morpholine ring, and a piperazine ring (which may optionally be substituted with one or more of an alkyl group having 1 to 6 carbon atoms and an alkylsulfonyl group having 1 to 6 carbon atoms)), an alkoxy group having 1 to 6 carbon atoms, an alkylthio group having 1 to 6 carbon atoms, a halogen atom, a trifluoromethyl group, a difluoromethyl group, a cyano group, a phenyl group (which may optionally be substituted with one or more of an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, and a halogen atom), a carboxyl group, or $-CO_2R_5$.

12. The pyridine derivative or the pharmaceutically acceptable salt thereof, or the solvate thereof according to claim 11, wherein R_3 is a hydrogen atom, a methyl group, an ethyl group, an isopropyl group, a cyclopropyl group, a chlorine atom, a bromine atom, an iodine atom, a trifluoromethyl group, a difluoromethyl group, a methoxy group, a phenyl group, a cyano group, ~~an acetyl group,~~ a carboxyl group, $-CO_2R_5$, a hydroxymethyl group, a 1-hydroxyethyl group, a 2-hydroxypropan-2-yl group, a 3-hydroxypentan-3-yl group, a dimethylaminomethyl group, a diethylaminomethyl group, or a morpholin-4-ylmethyl group.

13. The pyridine derivative or the pharmaceutically acceptable salt thereof, or the solvate thereof according to any of claims 1 to 12, wherein R_4 is a carboxyl group